Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences
Dr. Jamal Ouazzani completed his PhD in applied microbiology in 1988 from Paris XI University-France and obtained a permanent research position at the National Center for Scientific Research CNRS in 1989 (www.cnrs.fr). Since 2014, he has held the position of CNRS Research Director within the Institute for Chemistry of Natural Compounds (ICSN, www.icsn.cnrs-gif.fr) and leads the ICSN Pilot-Unit (www.pilotunit.com). Dr. J. Ouazzani has an interdisciplinary profile covering fundamental and applied microbiology, natural product chemistry, biochemistry, biocatalysis, bioremediation, innovative biotechnology design, building and implementation. He has been engaged in diverse consulting activities since 1996, for environmental, cosmetic and pharmaceutical companies. He has published more than 62 publications in peer-reviewed journals and has obtained nine patents. The ICSN Pilot Unit benefits from European, regional and national grants in the context of eight collaborative projects, including coordinating the EU-H2020 project TASCMAR (www.tascmar.eu). Dr. Ouazzani collaborates with various companies in the field of ethno-pharmacology, bioactive natural compounds from plants, marine organisms and microorganisms, innovative extraction and bio-resource cultivation technologies.
Neurodegenerative diseases (NDs) cover various pathologies and associated disorders. The most known and disabling are Alzheimer’s disease, Parkinson’s disease and Huntington’s disease, causing motor disorders and dementia. NDs affect the ageing population and represent one of the most challenging public health issues worldwide. The situation is particularly critical due to the increasing number of patients, the cost of treatment, and the societal impact of day-to-day care and dependence. As an example, around 7 million European citizens suffer from Alzheimer's disease with a total care cost reaching 155 billion euros each year. Besides existing drugs adressing the symptoms rather than the cause, alternative natural solutions based on natural extracts or pure compounds are driving growing interest. This presentation begins with an overview of the current state of the art in the use of natural resources and the products they contain, to combat the potential causes and consequences of NDs. We will then move on to the results we have obtained in the field, by using innovative extraction technologies and controlled biotransformation processes to enhance the effectiveness and the safety of the end products.